8-K: Nurix Outlines 2026 Goals, Advances Degrader Pipeline

Nurix Therapeutics presented its 2025 performance and 2026 strategic objectives at the J.P. Morgan Healthcare Conference, focusing on advancing its targeted protein degradation pipeline.

Summary

• 2025 was a breakthrough year, achieving several key milestones in clinical execution, pipeline momentum, and financial strengthening.
• Initiated the pivotal DAYBreak-201 Phase 2 study for bexobrutideg in relapsed/refractory CLL, designed to support Accelerated Approval.
• Bexobrutideg demonstrated robust clinical activity at ASH 2025, with an 83% objective response rate (ORR) and a 22.1-month median progression-free survival (PFS) in r/r CLL patients with a median of four prior lines of therapy.
• The 600 mg dose for bexobrutideg was secured per Project Optimus, showing a trend toward higher ORR and PFS without an increase in adverse events.
• Partner Gilead initiated a Phase 1 SAD/MAD study for the IRAK4 degrader (GS-6791).
• Partner Sanofi advanced the STAT6 degrader (NX-3911) to IND-enabling studies.
• Initiated healthy volunteer studies with a new bexobrutideg formulation for inflammation & immunology (I&I).
• Strengthened the balance sheet with a $250 million follow-on offering and earned $47 million in non-dilutive capital through discovery partnerships.
• Reported pro forma cash/investments of $663.8 million, including the net proceeds from the October 2025 registered direct offering.
• NX-1607 (CBL-B Inhibitor) Phase 1a data showed immune activation and clinical activity, including a confirmed partial response in micro-satellite stable colorectal cancer (MSS CRC).
• Strengthened leadership with the appointment of a Chief Commercial Officer and two new board members with deep drug development and commercialization experience.

Sentiment

Score: 8

Explanation: The filing highlights significant clinical progress for its lead candidate, bexobrutideg, with superior efficacy metrics compared to a recently approved competitor in a more challenging patient population. Strong financial position, advancement of multiple pipeline programs (both wholly-owned and partnered), and positive early data for NX-1607 contribute to a very positive outlook. The initiation of pivotal trials and clear strategic goals for 2026 further reinforce this sentiment.

Positives

• Bexobrutideg achieved an 83% objective response rate and 22.1-month median progression-free survival in relapsed/refractory CLL patients, demonstrating strong efficacy and durability.
• The 600 mg dose of bexobrutideg was cleared by regulators for pivotal studies, showing a trend towards higher ORR and PFS without increased adverse events.
• Successful initiation of the pivotal DAYBreak CLL-201 Phase 2 study for bexobrutideg, targeting accelerated approval.
• Strong financial position with $663.8 million in pro forma cash/investments and $47 million in non-dilutive capital from partnerships.
• Positive Phase 1a clinical data for NX-1607, demonstrating immune activation and clinical activity, including a confirmed partial response in a difficult-to-treat tumor type (MSS CRC).
• Advancement of partnered programs: Gilead initiated Phase 1 for IRAK4 degrader (GS-6791), and Sanofi advanced STAT6 degrader (NX-3911) to IND-enabling studies.
• Expansion of bexobrutideg into I&I indications with a new tablet formulation entering Phase 1 testing.
• Strengthened leadership team with key appointments in commercial and board roles.

Risks

• Uncertainty regarding the ability to advance, obtain regulatory approval of, and commercialize current and prospective drug candidates (bexobrutideg, zelebrudomide, NX-1607).
• Inherent risks and uncertainties in the drug discovery and drug development process.
• Uncertainties regarding the timing and results of clinical trials.
• Ability to fund development activities and achieve development goals.
• Risks related to collaboration partners, including speed of development of partnered programs and timing/receipt of payments (milestone, royalties).
• Impact of macroeconomic events and conditions (financial market volatility, inflation, interest rate fluctuations, global banking instability, federal budget/debt ceiling uncertainty, war, conflicts, pandemics) on clinical trials and operations.
• Ability to protect intellectual property.
• Animal model data, in vitro potency data, and proteomics data may not predict human efficacy.

Future Outlook

Nurix aims to make 2026 a transformative year by executing the pivotal DAYBreak CLL-201 study and initiating the confirmatory Phase 3 trial (DAYBreak CLL-306) for bexobrutideg. The company plans to initiate a Phase 1b/2 combination study for bexobrutideg in CLL and expand it into autoimmune and inflammatory indications with a new tablet formulation, targeting an IND submission in 2026. Nurix also anticipates potential Phase 1 results for the GS-6791 IRAK4 degrader from Gilead and a potential IND filing for the NX-3911 STAT6 degrader by Sanofi. The company will continue to leverage its DEL-AI platform for drug discovery and expects to earn additional research milestones and licensing fees from collaborations.

Management Comments

• "2025 was a defining year for Nurix, having advanced our potentially best-in-class BTK degrader, bexobrutideg, into pivotal development for patients with relapsed or refractory CLL."
• "As we enter 2026, we are focused on executing the DAYBreak CLL-201 study and initiating the confirmatory Phase 3 trial, DAYBreak CLL-306."
• "We are also excited to advance our pipeline of wholly owned and partnered programs in inflammation and autoimmune diseases, including our new tablet formulation of bexobrutideg, our IRAK4 degrader program partnered with Gilead, and our STAT6 degrader program partnered with Sanofi."
• "With our pivotal DAYBreak program underway, a strong balance sheet, and multiple catalysts across oncology and immunology, we believe Nurix is exceptionally well positioned to make 2026 a transformative year for the Company and the field of targeted protein degradation."

Industry Context

Nurix is positioning its targeted protein degradation (TPD) platform at the forefront of drug development, aiming to outmatch cancer and autoimmune diseases. The company's lead candidate, bexobrutideg, targets BTK, a clinically and commercially proven target, with a novel mechanism of action that removes both enzymatic activity and scaffolding functions, unlike traditional BTK inhibitors. The broader TPD field is seen as the next frontier in drug development, following antibodies, small molecule inhibitors, and nucleic acid-based therapies. Nurix's collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer underscore the industry's interest in this modality for both oncology and inflammation/autoimmune indications, where annual sales for related targets are in the tens to hundreds of billions of dollars.

Comparison to Industry Standards

• Bexobrutideg's Objective Response Rate (ORR) of 83.0% compares favorably to pirtobrutinib's 65% (69% investigator-assessed) in a more heavily pretreated patient population.
• Bexobrutideg's Median Duration of Response (DOR) of 20.1 months is longer than pirtobrutinib's 13.8 months (13.9 investigator-assessed).
• Bexobrutideg's Median Progression-Free Survival (PFS) of 22.1 months is significantly longer than pirtobrutinib's 14.0 months.
• Bexobrutideg was evaluated in a patient population with a median of 4 prior lines of therapy, compared to pirtobrutinib's 3, and had higher exposure to prior non-covalent BTK inhibitors (27% vs 0%) and BCL-2 inhibitors (83% vs 50%).
• Bexobrutideg demonstrates superior mutational coverage compared to BTK inhibitors, showing most potent cell killing across various BTK mutations (WT, C481S, C481R, V416L, T474I, L528W).
• Bexobrutideg is the only BTK degrader to demonstrate clinical activity in patients with CNS disease, including complete responses.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through clinical advancements, strong financial position, and pipeline expansion.
• Patients: Potential for improved treatment options for relapsed/refractory CLL and other B-cell malignancies with bexobrutideg, and future treatments for various cancers and autoimmune diseases from the broader pipeline.
• Employees: Continued growth and development opportunities within a company advancing multiple clinical programs.
• Collaboration Partners (Gilead, Sanofi, Pfizer): Continued progress in partnered programs and potential for future milestone and royalty payments.

Next Steps

• Continue enrollment of the pivotal Phase 2 trial, DAYBreak CLL-201.
• Initiate a confirmatory Phase 3 study (DAYBreak CLL-306) in r/r CLL in 2026, comparing bexobrutideg monotherapy to pirtobrutinib.
• Initiate a Phase 1b/2 clinical study in CLL in combination with other therapeutic agents, including venetoclax, in 2026.
• Submit an IND for bexobrutideg's new tablet formulation for I&I indications in 2026.
• Potential Phase 1 results for GS-6791 IRAK4 degrader from Gilead.
• Potential IND filing for NX-3911 STAT6 degrader by Sanofi.
• Report ongoing clinical data updates for bexobrutideg Phase 1a/b CLL and NHL cohorts, and Zelebrudomide Phase 1a cohorts.
• Progress research and development pipeline by leveraging the DEL-AI platform.
• Earn additional research milestones and potential licensing fees from collaborations.

Key Dates

Recommendation

The company has presented compelling clinical data for bexobrutideg, demonstrating superior efficacy (ORR 83%, PFS 22.1 months) compared to a recently approved competitor (pirtobrutinib) in a more challenging, heavily pretreated patient population. The successful selection of the optimal dose and initiation of a pivotal Phase 2 study for accelerated approval, with a confirmatory Phase 3 planned, de-risks the lead asset significantly. Furthermore, the strong financial position with over $660 million in pro forma cash, the advancement of multiple wholly-owned and partnered pipeline programs (including positive early data for NX-1607), and strategic leadership appointments indicate robust operational execution and future growth potential in the high-value targeted protein degradation space. These factors collectively suggest a strong investment opportunity.

Keywords

Nurix Therapeutics, NRIX, BTK degrader, Bexobrutideg, NX-5948, CLL, Chronic Lymphocytic Leukemia, Targeted Protein Degradation, Oncology, Autoimmune Disease, Inflammation, IRAK4 degrader, STAT6 degrader, NX-1607, CBL-B Inhibitor, Clinical Trials, Phase 2, Phase 3, Accelerated Approval, J.P. Morgan Healthcare Conference, Biopharmaceutical, Drug Development, Immunology, DEL-AI platform